Verrica Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
4.1%projected annual EPS growth
Analyst Coverage
5analysts covering
Monitoring Framework
Key Performance Indicators
YCANTH Dispensed Applicator Units Quarterly15.3K
U.S. YCANTH Net Product Revenue Quarterly4.3M
Total Revenue Quarterly5M
Watch Items
- Cash Runway and Funding NeedsTrigger: Cash balance falling below $10 million or runway dropping under 6 monthsAction: Evaluate dilutive equity financing options, strategic partnerships, or additional licensing agreements to extend runway beyond Q1 2027.
- Phase 3 Common Warts Program ProgressTrigger: Initiation of the second Phase 3 trial in the US and JapanAction: Monitor enrollment rates and clinical milestones; coordinate with partner Torii Pharmaceutical to manage development costs.
- VP-315 Phase 3 Trial PreparationTrigger: FDA alignment on Phase 3 protocol for basal cell carcinomaAction: Assess trial design, projected R&D expenses, and potential clinical timelines for the lead oncology asset.
Research as of 19 Jun 2026